Novo Nordisk Hunts for Deals After Losing Metsera to Pfizer
Novo Nordisk CEO says company is open to acquisitions of any size to strengthen its obesity drug portfolio following competition from Eli Lilly and loss of Metsera to Pfizer.
/ 3 items
#GPCR↓
Novo Nordisk Wins FDA Approval for Wegovy Weight-Loss Pill, Beating Lilly to Market
Novo Nordisk's Wegovy pill becomes the first FDA-approved oral GLP-1 weight-loss medication, launching January 2026 at $149/month as the Danish drugmaker aims to reclaim market share from Eli Lilly.
Structure Therapeutics' Obesity Pill Shows Promising Weight Loss Results, Shares Surge
Structure Therapeutics' (GPCR) experimental obesity pill aleniglipron delivers up to 15.3% weight loss in clinical trials, positioning it as a competitive alternative to Eli Lilly's oral treatment with shares more than doubling on promising Phase 2 results.